Vericel Co. (NASDAQ:VCEL) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP decreased its holdings in Vericel Co. (NASDAQ:VCEL) by 34.4% in the 3rd quarter, Holdings Channel reports. The firm owned 14,823 shares of the biotechnology company’s stock after selling 7,788 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Vericel were worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Vericel by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock valued at $177,567,000 after buying an additional 39,349 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Vericel by 7.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 58,377 shares of the biotechnology company’s stock valued at $3,036,000 after acquiring an additional 4,227 shares during the last quarter. Advisors Asset Management Inc. lifted its position in Vericel by 25.7% during the 1st quarter. Advisors Asset Management Inc. now owns 16,508 shares of the biotechnology company’s stock worth $859,000 after acquiring an additional 3,374 shares during the period. Lazard Asset Management LLC lifted its position in Vericel by 178.7% during the 1st quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,657 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Vericel by 6.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 27,280 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 1,721 shares during the last quarter.

Vericel Stock Down 0.8 %

NASDAQ:VCEL opened at $58.62 on Tuesday. The firm’s fifty day simple moving average is $46.41 and its 200-day simple moving average is $47.07. The stock has a market cap of $2.89 billion, a PE ratio of 977.00 and a beta of 1.66. Vericel Co. has a fifty-two week low of $32.31 and a fifty-two week high of $61.49.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Equities analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current year.

Insiders Place Their Bets

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the sale, the director now owns 26,595 shares of the company’s stock, valued at $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This trade represents a 7.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,666 shares of company stock worth $1,350,764. 5.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on VCEL. Canaccord Genuity Group initiated coverage on Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Canaccord Genuity Group reiterated a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Tuesday, November 19th. Finally, Stephens increased their price target on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $58.14.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.